archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL Limited investor relations section, an online resource
    We produce safe and effective therapies for patients who rely on them for their quality of life and sometimes for life itself ASX Releases 16 10 2013 CSL announces A 950m share buyback CSL Limited ASX CSL today announced a further on market share buyback of up to A 950 million Speaking at CSL s Annual General Meeting in Melbourne today CSL Chairman Professor John Shine said the Board was pleased to continue a buyback program that had clearly delivered benefits for shareholders More 07 10 2013 Agreement to settle U S antitrust class action litigation Profit outlook re affirmed subject to settlement CSL Limited ASX CSL today announced that it has signed an agreement to settle the U S antitrust class action litigation filed by certain U S and Puerto Rican hospital groups which has been ongoing since 2009 The settlement agreement resolves and dismisses all claims and potential claims of class members against CSL in the lawsuit as well as those against the Plasma Protein Therapeutics Association an industry trade association More 14 08 2013 Full Year Results announcement for 2012 13 CSL Limited ASX CSL today announced a net profit after tax NPAT of US 1 216 million for the twelve months ended 30 June 2013 up US 192 million or 19 on a reported basis when compared to the prior comparable period PCP The result included an unfavourable foreign exchange impact of US 18 million On a constant currency1 basis net profit after tax grew 21 slightly ahead of guidance Earnings per share grew 24 benefiting from current and past capital management initiatives More 14 08 2013 CSL announces Changes to the Board CSL Limited ASX CSL today announced that Ms Marie McDonald has been appointed a Director effective from 14 August 2013 The Company also announced that Mr Ian Renard AM has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company s Annual General Meeting on 16 October 2013 More 08 08 2013 Notice of Investor Analyst Briefing Result FY2013 CSL Limited ASX CSL CSL Limited s 2013 full year results will be announced on Wednesday 14 August 2013 More 28 06 2013 Terms of Departure of Managing Director and CEO CSL Limited ASX CSL has previously announced that Dr Brian McNamee will be succeeded by Mr Paul Perreault as Managing Director and Chief Executive Officer of CSL from 1 July 2013 More 19 06 2013 CSL Limited Changes to Segment Reporting In February 2013 the Company announced the completion of the reorganisation of its Australian Operations which took effect from 1 January 2013 and advised that financial reporting reflecting this new organisational structure would be shown in the segment reporting commencing with the FY2013 results More 05 04 2013 CSL Half Year Report 2012 13 In February 2013 the Company announced the completion of the reorganisation of its Australian Operations which took effect from 1 January 2013 and advised that financial reporting reflecting this new organisational

    Original URL path: http://www.csl.com.au/investors (2014-01-05)
    Open archived version from archive


  • Corporate Responsibility
    business goals and ensure that it complements our unique capabilities and benefits our diverse set of stakeholders Our Corporate Responsibility Priority Areas Researching and developing new medicines for unmet needs while continually improving our protein based therapies for patients Ensuring our therapies are safe and of the highest quality by maintaining the highest standards throughout all stages of the product life cycle Operating responsibly in the marketplace by marketing our medicines in an ethical manner working with others to improve equity of access and sharing our financial success Providing a positive working environment for our people by engendering a culture of mutual trust and respect enabling them to do their jobs safely and effectively and rewarding and recognising their contributions Supporting our patient biomedical and local communities by improving access to our therapies and enhancing the quality of life for patients advancing scientific knowledge and supporting future medical researchers and engaging our staff in the support of local communities and Minimising our impacts on the environment through the responsible management of our operations and natural resources without compromising the safety quality and accessibility of our therapies Governance Our values form the foundation of CSL s global commitment to CR Our

    Original URL path: http://www.csl.com.au/corporate-responsibility.htm (2014-01-05)
    Open archived version from archive

  • Jobs and career opportunities at CSL Limited
    company that develops manufactures and markets products to treat and prevent a range of serious human medical conditions A leader in our field CSL is a successful company operating in 27 countries with over 10 000 employees Each employee has the opportunity to play a role in improving people s health and in many cases saving lives At CSL not only is it critical to have the experience and qualifications

    Original URL path: http://www.csl.com.au/careers (2014-01-05)
    Open archived version from archive

  • CSL Limited press releases and corporate communications
    2009 The settlement agreement resolves and dismisses all claims and potential claims of class members against CSL in the lawsuit as well as those against the Plasma Protein Therapeutics Association an industry trade association More 14 08 2013 Full Year Results announcement for 2012 13 CSL Limited ASX CSL today announced a net profit after tax NPAT of US 1 216 million for the twelve months ended 30 June 2013 up US 192 million or 19 on a reported basis when compared to the prior comparable period PCP The result included an unfavourable foreign exchange impact of US 18 million On a constant currency1 basis net profit after tax grew 21 slightly ahead of guidance Earnings per share grew 24 benefiting from current and past capital management initiatives More 14 08 2013 CSL announces Changes to the Board CSL Limited ASX CSL today announced that Ms Marie McDonald has been appointed a Director effective from 14 August 2013 The Company also announced that Mr Ian Renard AM has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company s Annual General Meeting on 16 October 2013 More 08 08 2013 Notice of Investor Analyst Briefing Result FY2013 CSL Limited ASX CSL CSL Limited s 2013 full year results will be announced on Wednesday 14 August 2013 More 04 07 2013 CSL progresses new bleeding disorder therapies CSL Limited has this week presented promising results from a number of clinical studies involving a new group of therapies for the treatment of haemophilia More 28 06 2013 Terms of Departure of Managing Director and CEO CSL Limited ASX CSL has previously announced that Dr Brian McNamee will be succeeded by Mr Paul Perreault as Managing Director and Chief Executive Officer of CSL from 1 July 2013 More 19 06 2013 CSL Limited Changes to Segment Reporting In February 2013 the Company announced the completion of the reorganisation of its Australian Operations which took effect from 1 January 2013 and advised that financial reporting reflecting this new organisational structure would be shown in the segment reporting commencing with the FY2013 results More 30 04 2013 bioCSL Goes Back into Influenza Vaccine Production for Australia bioCSL announced today that it has recently restarted production of influenza vaccine for the Australian market in response to higher than expected demand this season More 29 04 2013 bioCSL Awarded Major Vaccine Distribution Contracts bioCSL has been selected by New South Wales Health NSW Health and the Western Australian Department of Health WA DoH to provide storage and distribution services for government funded vaccine programs The contracts awarded after separate tender processes have a combined value of 6 8 million More 05 04 2013 CSL Half Year Report 2012 13 bioCSL has been selected by New South Wales Health NSW Health and the Western Australian Department of Health WA DoH to provide storage and distribution services for government funded vaccine programs The contracts awarded after separate tender processes have a combined

    Original URL path: http://www.csl.com.au/newsroom (2014-01-05)
    Open archived version from archive

  • CSL Limited - Contact Information
    we offer vary from country to country Please choose a country for more specific details Country Please select Argentina Australia Austria Belgium Brazil Canada China Denmark France Germany Greece Hong Kong Italy Japan Malaysia Mexico Netherlands New Zealand Portugal Spain Sweden Switzerland UK USA Key Contacts CSL Corporate Registered Head Office 45 Poplar Rd Parkville Victoria 3052 Australia Phone 61 3 9389 1911 Fax 61 3 9389 1434 Submit General Enquiries CSL Behring Corporate Office USA 1020 First Avenue PO Box 61501 King of Prussia PA 19406 0901 USA Phone 1 610 878 4000 Fax 1 610 878 4009 Careers Employment Opportunities at CSL 45 Poplar Rd Parkville Victoria 3052 Australia Submit General Enquiries CSL Direct Portal for ordering Australian plasma products and vaccines CSL Direct website Portal enquiries 1800 008 275 Media Enquiries CSL Limited Sharon McHale Senior Director Public Affairs Mobile 61 409 978 314 Phone 613 9389 1506 Email sharon mchale csl com au 45 Poplar Rd Parkville Victoria 3052 Australia Media Enquiries CSL Behring Chris Florentz Phone 1 610 878 4316 Fax 1 610 290 9316 Email Christopher Florentz cslbehring com 1020 First Avenue PO Box 61501 King of Prussia PA 19406 0901 USA Investor Relations

    Original URL path: http://www.csl.com.au/contact-csl (2014-01-05)
    Open archived version from archive

  • CSL Limited - Annual General Meeting
    2013 CSL Limited Annual General Meeting was held on Wednesday 16 October 2013 at 10 00am at the Function Centre National Tennis Centre Melbourne Park Batman Avenue Melbourne A recording of the meeting can be accessed via the webcast link below AGM Webcast 2013 Chairman s Address 0 1Mb 2013 MD Presentation 1Mb Responses to shareholder questions received 0 2Mb Past Annual General Meetings 17 October 2012 2012 Chairman s

    Original URL path: http://www.csl.com.au/investors/briefings-presentations/annual-general-meeting.htm (2014-01-05)
    Open archived version from archive

  • CSL signs agreement with Janssen to progress novel cancer therapy
    cell populations thought to mediate autoimmune diseases such as lupus The agreement with Janssen was announced by CSL s Chief Scientific Officer Dr Andrew Cuthbertson at the Company s annual R D briefing for investors CSL362 is at a very exciting stage of development and required a partner with a proven capability in oncology and autoimmunity to maximise its potential We are delighted to have attracted such a high quality partner in Janssen who share a deep commitment to developing this promising therapy for the benefit of very ill patients said Dr Cuthbertson CSL362 was engineered by CSL scientists using as a starting point a unique antibody developed by Professor Angel Lopez at Adelaide s Centre for Cancer Biology in the late 1990 s The original antibody was able to recognise AML cells preferentially but was not suitable for use in humans and it lacked the ability to recruit and activate the body s NK cells CSL scientists engineered the antibody to ensure that it is suitable for use in humans and to enhance its ability to recruit NK cells to kill the AML cells The development of CSL362 to date is another fine example of the power of collaboration and speaks to the outstanding quality of science in Australia s medical research institutions With the addition of Janssen we have the modern model of drug development which uses the distinctive strengths of all parties to bring new therapies to patients sooner said Dr Cuthbertson The clinical trial for CSL362 is being conducted in Australia and the USA The Australian study is being led by Professor Andrew Roberts who is a clinical haematologist at the Royal Melbourne Hospital Head of Clinical Translation at the Walter and Eliza Hall Institute and Metcalf Chair of Leukaemia Research at the University of Melbourne

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252897540657/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL releases positive data for potential new heart attack therapy and announces next phase of clinical development
    blind placebo controlled trial that evaluated the effects of a single dose administration of CSL112 in 44 patients over a 90 day period In addition to positive results for key biological indicators the trial data also demonstrated favourable safety and tolerability for this potential new therapy and have given CSL confidence to proceed to a phase 2b study Patients who experience an acute coronary event have a high risk of suffering another heart attack stroke or other cardiovascular event particularly within the first 30 days said Dr Andrew Cuthbertson Chief Scientist for CSL The results of this clinical study of CSL112 support our continued enthusiasm for its development as a novel approach to address this important treatment void CSL has announced a global phase 2b clinical trial program which will include sites in Australia The trial will seek to assess multiple dose administration of CSL112 compared with placebo in approximately 1 200 heart attack patients The final design of the trial is currently being reviewed by regulators Professor Professor Philip Aylward Cardiologist at the South Australian Health and Medical Research Institute and Director of Medicine Cardiac and Critical Care at Flinders Medical Centre will lead the Australian arm of the study which will involve a number of sites nationally We know there is a need for better approaches to reduce the high risk of early recurrent cardiovascular events after a heart attack said Professor Aylward CSL112 is a promising treatment targeting the unstable coronary plaques causing these events and deserves further investigation CSL112 was developed by CSL scientists in Australia and other global sites and has benefitted from collaborations with a number of medical research institutions including the Baker IDI Heart Diabetes Institute in Melbourne Australia Professor Bronwyn Kingwell Head of Metabolic and Vascular Physiology at the Baker IDI Institute

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252897412903/prdetail.htm (2014-01-05)
    Open archived version from archive